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Cardiopulmonary Support and Physiology Mitani et alAtrial natriuretic peptide gene transfection with a novel
envelope vector system ameliorates pulmonary
hypertension in rats
Yoshihide Mitani, MD, PhD,a Junko Maruyama, MD, PhD,b Bao Hua Jiang, MD, PhD,c Hirofumi Sawada, MD, PhD,a
Hideto Shimpo, MD, PhD,d Kyoko Imanaka–Yoshida, MD, PhD,e Yasufumi Kaneda, MD, PhD,f Yoshihiro
Komada, MD, PhD,a and Kazuo Maruyama, MD, PhDcObjectives: A novel hemagglutinating virus of Japan (HVJ, a murine parainfluenza
virus) envelope vector system, in which DNA is incorporated into an inactivated viral
particle deprived of its genome, was recently developed as a ready-to-use vector for
gene therapy. We therefore investigated whether intratracheal gene transfer using
this vector can induce transgene expression in the lung and whether atrial natriuretic
peptide gene transfer ameliorates pulmonary hypertension in rats.
Methods: Rats transfected intratracheally with b-galactosidase vector, atrial
natriuretic peptide vector, or mock vector were investigated for the evaluation of
b-galactosidase expression, atrial natriuretic peptide mRNA expression, and inflam-
matory cell infiltration. Rats were divided into 5 treatment groups (n 5 73):
normoxic rats treated intratracheally with mock vector or atrial natriuretic peptide
gene and chronic hypoxic rats treated similarly with mock vector, atrial natriuretic
peptide, or a reporter gene, b-galactosidase. Pulmonary hypertension and transfected
gene expression were evaluated.
Results: b-Galactosidase gene transfer induced its intense enzymatic activity in bron-
chial and alveolar epithelial cells but not in other organs in normoxic rats. Transfected
lungs were not associated with inflammatory cell infiltration. Atrial natriuretic peptide
gene transfection inhibited pulmonary hypertension, which is associated with its
mRNA expression in the lungs. Indices of right ventricular hypertrophy and
pulmonary vascular diseases induced by chronic hypoxia were significantly but
incompletely ameliorated.
Conclusions: HVJ-envelope vector is an efficient, relatively safe, and ready-to-use
gene delivery system for pulmonary vascular diseases. Atrial natriuretic peptide
gene transfer to lungs by using this vector could be a promising therapeutic approach
against pulmonary hypertension.
T
he development of efficient and safe vector systems is a major challenge in the
clinical application of gene therapy against pulmonary hypertension. Initial
gene transfer experiments for the lungs, performed by using adenoviral
vectors, provoked significant inflammatory responses, which limited the duration of
gene expression in animal models1,2 and their clinical utility in human trials.3,4 The
delivery of other current viral vectors (retroviral and adeno-associated viral vectors)
results in the incorporation of the exogenous DNA into the host genome, which raises
concerns for the development of malignant disorders.5,6 Recently, a novel hemagglu-
tinating virus of Japan (HVJ, a murine parainfluenza virus) envelope vector system
was developed, in which plasmid DNA was incorporated into the lipid envelope of
the inactivated virus deprived of the viral genome.7 Although previous nonviral
vectors have limited transfection efficiency in vivo, this gene delivery system confers
high transfection efficiency in vivo and in vitro by means of a specific HVJ-cell fusion
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PAbbreviations and Acronyms
ANP 5 atrial natriuretic peptide
LV1S 5 left ventricle plus septum
PA 5 pulmonary artery
PBS 5 phosphate-buffered saline
RV 5 right ventricle
VCAM-1 5 vascular cell adhesion molecule 1
machinery.7 In addition, this is a new ready-to-use vector for
gene therapy, which is more easily prepared compared with
the previous HVJ-liposome vector.8 However, the biologic
relevance of this transfection system has not been established
in the lungs, and intratracheal gene transfer with this system
has not been applied to gene transfer experiments against
pulmonary hypertension.
Accumulated evidence suggests that atrial natriuretic
peptide (ANP) plays a pivotal role in counteracting the mech-
anisms involved in the development of pulmonary hyperten-
sion. Importantly, pulmonary vasodilator responses to ANP
are well preserved or exaggerated in pulmonary hyperten-
sion.9,10 Moreover, treatments that increase ANP levels,
either by means of ANP supplementation or inhibition of
the neutral endopeptidase that degrades ANP in vivo, attenu-
ate pulmonary hypertension and vascular remodeling.11,12
Therefore ANP gene transfer to the lungs is warranted as
a therapeutic approach against pulmonary hypertension.
We therefore investigated whether efficient gene transfer
to the lungs can be conferred by the novel HVJ-envelope vec-
tor system and whether this system is of biologic relevance in
inhibiting the development of pulmonary hypertension and
vascular diseases in rats by means of ANP gene transfer.
Materials and Methods
Plasmids, Preparation of HVJ-envelope Vector, and
Intratracheal Gene Transfer
The expression vector for rat ANP was constructed as previously
described.13 In brief, a fragment containing rat ANP cDNA was
inserted into the XhoI site of the pUC-CAGGS expression vector
plasmid. The expression vector for the b-galactosidase gene (Lac
Z) was similarly constructed. In this plasmid transcription of the
ANP or Lac Z cDNA was under the control of the chicken b-actin
promoter and the cytomegalovirus enhancer. It has been verified
that cells transfected with the pUC/ANP construct release biologi-
cally active ANP peptide into the cell culture medium.13 HVJ-enve-
lope vector was prepared as described previously.7 Briefly, the virus
suspension (10,000 hemagglutinating units) was inactivated by
means of UV irradiation (99 mJ/cm2) and mixed with plasmid
DNA (200 mg) and 0.3% Triton-X. After centrifugation, it was
washed with 1 mL of balanced salt solution (10 mmol/L Tris-Cl
[pH 7.5], 137 mmol/L NaCl, and 5.4 mmol/L KCl) to remove the
detergent and unincorporated DNA. After centrifugation, the
envelope vector was suspended in 100 mL of phosphate-buffered
saline (PBS). The vector was stored at 4C until use. HVJ-envelopeThe Journal of Thovector solution (0.2 mL) including 50 mg of Lac Z or ANP gene or
the empty vector solution was injected through a 24-gauge intravas-
cular catheter (TERUMO, Tokyo, Japan) into the trachea, which is
pre-exposed by means of a midline skin incision after achievement
of pentobarbital sodium anesthesia (33 mg/kg by means of intraper-
itoneal injection) while not ventilated.
b-Galactosidase Expression, Rat ANP Reverse
Transcriptase–Polymerase Chain Reaction, and
Immunohistochemistry
Rats 4 days after Lac Z, ANP vector, or mock transfection or not
transfected through the trachea were killed after achievement of
pentobarbital sodium anesthesia for the evaluation of b-galactosi-
dase expression, ANP mRNA expression, and inflammatory cell
infiltration.
The lungs were perfused with PBS through a pulmonary artery
(PA) cannula, fixed with 1% glutaraldehyde in PBS through PA
and tracheal cannulae at 4C for 4 hours, and subsequently substituted
with and immersed in cold PBS containing 30% sucrose overnight
before being embedded and frozen in Tissue-Tek OCT compound
(Miles Inc., IN) to evaluate b-galactosidase expression. TheX-gal as-
say was performed as follows.14 Cryostat sections (4-mm slice) were
washed with PBS and incubated at 37C for 4 hours in an X-gal
solution (in PBS: 1 mg/mL X-gal [Sigma, St Louis, Mo; in
dimethyl sulfoxide], 5 mmol/L K3Fe[CN]6, 5 mmol/L K4Fe(CN)6,
and 2 mmol/L MgCl2). The sections were washed in water, counter-
stained with hematoxylin, dehydrated with ethanol, and mounted to
stop the enzymatic reaction. Some sections were subsequently incu-
bated with biotinated smooth muscle a-actin (Sigma) for 1 hour
and visualized with 30, 30-diaminobenzidine to distinguish between
smooth muscle cells and b-galactosidase–positive cells.
For the evaluation of rat ANP expression, total RNA was
extracted from rat lungs, which were carefully isolated from the
trachea and bronchi, by using a modified single-step acid-guanidine
thiocyanate-phenol-chloroform method15 with ISOGEN reagent
(Nippon Gene, Tokyo, Japan). The ethanol-precipitated RNA
fraction (1 mg) was reverse transcribed with SuperScript II reverse
transcriptase (GIBCO BRL, Gaithersburg, Md), according to the
manufacturer’s protocol, and 20 mL of first-strand cDNA solution
was obtained. Primer sequences for rat ANP were 50-AAC
CTG-CTA-GAC-CAC-CTG-30 and 50-TTT-TCA-AGA-GGG
CAG-ATC-30.16 Samples were kept at 95C for 10 minutes and
subjected to thermocycling (28 cycles of 30 seconds at 95C, 30
seconds at 55C, and 45 seconds at 72C, with a final extension
at 72C for 7 minutes) to amplify ANP cDNA, generating a 214-
bp fragment. Primer sequences for rat b-actin (internal controls)
were 50-GGG-AAA-TCG-TGC-GTG-ACA-T-30 and 50-CAG
GAG-GAG-CAA-TGA-TCT-T-30. Samples were kept at 95C for
15 minutes and subjected to thermocycling (25 cycles of 30 seconds
at 95C, 30 seconds at 55C, and 1 minute at 72C, with a final
extension at 72C for 5 minutes) to amplify b-actin cDNA, gener-
ating a 479-bp fragment. One microliter of a 20-mL reaction was run
on an agarose gel by using the DNA 7500 LabChip kit (Agilent
Technologies, Tokyo, Japan).
The lungs were perfused with PBS through a PA cannula, fixed
with 4% paraformaldehyde in PBS through PA and tracheal cannula
at 4C for 3 hours, and subsequently substituted with and immersed
in cold PBS containing 30% sucrose overnight before being
embedded and frozen in Tissue-Tek OCT compound to evaluateracic and Cardiovascular Surgery c Volume 136, Number 1 143
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onto glass slides and stored at 270C until use. Tissue sections
were air-dried, and nonspecific binding sites were blocked. Sections
were incubated overnight at 4Cwith primary antibodies that recog-
nize vascular cell adhesion molecule 1 (VCAM-1; 31000, mouse
monoclonal 5F10, Covance, NJ) and rat CD68 (3500, mouse
monoclonal ED-1, Serotec, Kidlington, UK).17 After streptavidin-
biotin amplification (LSAB2 kit, DAKO, Tokyo, Japan), the slides
were incubated with 30, 30-diaminobenzidine and counterstained
with hematoxylin. For the positive controls of immunohistochemis-
try, rats were intratracheally injected with lipopolysaccharide (Es-
cherichia coli lipopolysaccharide, serotype 055:B5, Sigma)
solution (6 mg/kg in 100 mL of PBS) and similarly killed 24 hours
after treatment.
Animal Models
Protocols for all animal experiments were approved by the Animal
Care Committee of Mie University School of Medicine. Pulmonary
hypertension was induced by exposure to chronic hypoxia in
7-week-old S-D rats weighing 190 to 230 g (CLEA Japan, Osaka,
Japan).18 Rats were randomly assigned to one of 5 groups: those
kept in ambient air and treated intratracheally with empty vector
or rat ANP gene by using the HVJ-envelope vector and those ex-
posed to hypobaric hypoxia (air at 380 mm Hg) for 10 days and
treated similarly with empty vector, rat ANP gene, or Lac Z. Rats
were transfected with 0.2 mL of the HVJ-envelope vector solution
3 days before hypoxic exposure. Food and water were provided ad li-
bitum throughout the experiment. Rats were removed from the hypo-
baric chamber once daily for 10minutes forweighing andnormal care.
Hemodynamic Measurements and Tissue Preparation
After the period of hypoxic exposure, rats were catheterized after
achievement of pentobarbital sodium anesthesia by using
a closed-chest technique, as described previously in detail.18,19
Briefly, a catheter of silicone elastomer tubing (0.31 mm ID and
0.65 mmOD) was inserted into the PA or the aorta through the right
external jugular vein or the internal carotid artery, respectively. PA
or aortic pressure was monitored by use of a physiologic transducer
(Uniflow, Baxter), an amplifier system (AP-620G, Nihon Koden),
and a monitor (Polygraph system, Nihon Koden). The catheter
was passed under the skin and exteriorized at the back of the
animal’s neck. At 48 hours after catheterization, PA or aortic pres-
sure was recorded in ambient air while the rat was fully conscious.
The hematocrit value was determined from a 0.1-mL blood sample.
In this model values of cardiac output did not differ significantly
between normoxic and hypoxic rats.20
After the hemodynamic measurements were completed, lung
tissue was prepared for morphometric analysis of the vasculature,
as previously described in detail.18,19 Briefly, after the rat was
mechanically ventilated after achievement of pentobarbital sodium
anesthesia, the lungs were perfused through a PA cannula with
a hot (60C) mixture of radiopaque barium and gelatin at 1000
mm H20 pressure for 5 minutes. Then the isolated lungs were
distended and fixed by perfused 10% formalin through a tracheal
tube at a pressure of 360 mmH2O for 72 hours. A 103 103 5–mm
tissue block obtained from the midsection of the left lung was
processed for light microscopy. Sections from paraffin blocks
were stained by using the elastic Van Gieson method. The right
ventricle (RV) was dissected from the left ventricle plus septum144 The Journal of Thoracic and Cardiovascular Surgery c Jul(LV1S) and weighed separately. The weight ratios RV/(LV1S)
and RV/final body weight were calculated.
Morphometric Analysis of PAs
Light microscopic slides were analyzed blindly without knowledge
of the treatment groups, as reported previously.18,19 Briefly, all
barium-filled arteries of larger than 15 mm in external diameter
were assessed at 3400 magnification. Each artery was first catego-
rized according to its accompanying airway (ie, a terminal bronchus,
respiratory bronchus, alveolar duct, or alveolar wall). The structure
of each artery was determined as muscular (ie, with a complete
medial coat of muscle), partially muscular (ie, with only a crescent
of muscle), or nonmuscular (ie, with no apparent muscle). The
percentage of muscular and partially muscular arteries at alveolar
wall and alveolar duct levels was determined. For all muscular
arteries with an external diameter of the media # 200 mm, the dis-
tance between external and internal elastic laminae was measured at
2 points across the lumen along the shortest curvature and expressed
as a percentage of medial wall thickness, which was calculated as
twice the average wall thickness divided by the external diameter.
Measurement of Plasma ANP Levels
Plasma ANP levels were measured 15 days after administration of
the mock vector and ANP plasmid in normoxic and hypoxic rats.
Blood samples were harvested through a PA catheter after PA
pressure measurements. The samples were assayed for rat ANP
with an RIA kit (S-2039, Peninsula Laboratories, Calif), according
to the supplier’s instructions.
Statistics
Data are presented as means 6 standard error. The differences
between multiple groups were compared by using a 1-way analysis
of variance, followed by the Scheffe F test. An unpaired Student t
test was used to compare 2 groups.
Results
Expression of b-galactosidase and ANP in Rats
Transfected by Using HVJ-envelope Vector
Four days after intratracheal Lac Z transfer, b-galactosidase
was diffusely expressed in bronchial and alveolar epithelial
cells (Figure 1, A–C) but not obvious in pulmonary vascular
endothelial or smooth muscle cells or in other organs tested
(heart, muscle, aorta, liver, and spleen; Figure 1, B). In
contrast, b-galactosidase was not expressed in lungs from
mock-transfected rats (data not shown).
Reverse transcriptase–polymerase chain reaction studies
demonstrated that intratracheal ANP transfection induced
mRNA expression in the lung on day 4. mRNA expression
was not induced in mock-transfected rat lungs (Figure 1, D).
VCAM-1 Expression and ED1-positive Cell
Infiltration in Transfected Rat Lungs
To determine whether an inflammatory reaction was induced
in lungs by means of intratracheal HVJ-envelope vector
administration, we examined ED1-positive mononuclear
cell infiltration and VCAM-1 expression in the lungs ofy 2008
Mitani et al Cardiopulmonary Support and PhysiologyFigure 1. b-Galactosidase expression
and atrial natriuretic peptide (ANP)
mRNA expression were induced in rat
lungs by HVJ-envelope vector–based
gene transfer. b-Galactosidase expres-
sion (bright blue) was induced in rat
lungs transfected through trachea
(n 5 10). Brown cells represent smooth
muscle a-actin–positive cells (A–C). b-
Galactosidase–positive cells are found
in bronchial (A) and alveolar (C) epithe-
lial cells but not in pulmonary vascular
endothelial or smooth muscle cells (B).
Gene transfer with ANP vector, but not
with mock vector, induced mRNA ex-
pression in the lungs, as evaluated by
means of reverse transcriptase–poly-
merase chain reaction (n 5 3; D).
Marker, Size marker; control ANP, ANP
gene itself used for transfection; mock
(under rat groups), rats transfected
with the mock vector; ANP (under rat groups), rats transfected with ANP vector. Arrowheads mark representative b-galactosidase–pos-
itive cells. Scale bars 5 50 mm. The 214-bp band represents an ANP fragment.CS
Pnormoxic rats 4 days after mock transfection or nontransfec-
tion. No obvious VCAM-1 expression was observed in the
pulmonary endothelium in both treatment groups (Figure 2,
A and B). Mock transfection did not increase ED1-positive
cells in the lungs (Figure 2,D, E,G, andH). Positive controls
for the staining of VCAM-1–positive endothelium and
ED-1–positive inflammatory cells were confirmed in
lipopolysaccharide-treated rats (data not shown). Lack of
positive staining without primary antibodies was confirmed
in vector-treated lungs (Figure 2, C, F, and I). In addition,
the findings suggestive of inflammatory lung damage (ie,
foci of mild damage to alveolar or bronchial epithelial cells
with edema or hemorrhage) were not found in the transfected
lungs.
Figure 2. No obvious inflammatory re-
sponses were provoked by vector trans-
fer with the HVJ-envelope vector. No
obvious vascular cell adhesion mole-
cule 1 (VCAM-1) expression (brown)
was observed in pulmonary endothe-
lium in either treatment group (vector
or no vector; A and B). Vector transfer
did not increase ED1-positive cells
(brown, arrows) in the lungs (D, E, G,
and H). Negative controls for each
staining were shown (C, F, and I). Pri-
mary antibodies: VCAM-1 (A and B),
ED-1 (D, E, G, and H), and no antibody
(C, F, and I). Bars 5 50 mm. N 5 3 in
each treatment group.
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CSPEffects of ANP Gene Transfer on Pulmonary
Hypertension
Mean PA pressure was similar in normoxic rats treated with
empty vector or ANP gene transfer. The pulmonary hyperten-
sion observed (mean PA pressure, 37.1 6 1.1 mm Hg in the
hypoxia/mock transfection group and 38.1 6 4.7 mm Hg in
the hypoxia/Lac Z transfection group vs 18.8 6 1.2 mm Hg
in the control/mock transfection group; P. .05, respectively)
was decreased byANP transfection (30.86 1.1mmHg vs the
hypoxia/mock transfection group and the hypoxia/Lac Z
transfection group; P , .05, respectively); Figure 3, A).
The RV/(LV1S) ratio was similar in normoxic rats with
mock or ANP gene transfection. The right ventricular hyper-
tension induced by chronic hypoxia (RV/[LV1S] ratio: 38.9
6 0.7 in the hypoxia/mock transfection group and 37.96 1.1
in the hypoxia/Lac Z transfection group vs 25.0 6 0.4 in the
control/mock transfection group; P , .05, respectively) was
ameliorated by ANP transfection (36.56 0.8 vs the hypoxia/
mock transfection group, P , .05; Figure 3, B).
Morphometric Analysis of PAs
Normoxic rats with mock or ANP transfection had a similar
degree of medial wall thickness. The degree of medial wall
thickness increased with chronic hypoxia (mitral wall thick-
ness: 3.82% 6 0.34% in the hypoxia/mock transfection
group and 4.68%6 0.42% in the hypoxia/Lac Z transfection
Figure 3. Atrial natriuretic peptide
(ANP) gene transfer incompletely but
significantly ameliorates pulmonary
hypertension and vascular diseases
(percentage of muscularization) in rats.
ANP transfection completely inhibited
the percentage of medial wall thick-
ness. Mean pulmonary artery (PA) pres-
sure (A), right ventricle/left ventricle
plus septum (RV/LV1S) weight ratio
(B), percentageofmedialwall thickness
(C), and percentage of muscularization
(D) are shown. *P < .05 versus the hyp-
oxia/mock transfection group; yP < .05
versus the hypoxia/b-galactosidase
transfection group. B-Gal, b-Galactosi-
dase transfection. The number of each
group is described in parentheses.
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.05, respectively) was inhibited by ANP transfection (2.95%
6 0.14% vs the hypoxia/mock transfection group and the
hypoxia/Lac Z transfection group; P , .05, respectively).
Lac Z transfection increased the degree of medial wall thick-
ness in hypoxic rats (hypoxia/Lac Z transfection group vs
hypoxia/mock transfection group, P , .05; Figure 3, C).
Normoxic rats with mock or ANP transfection had simi-
lar percentages of muscularization in small PA. The percent-
age of muscularization increased with chronic hypoxia
(32.5% 6 2.7% in the hypoxia/mock transfection group
and 43.6% 6 2.2% in the hypoxia/Lac Z transfection group
vs 9.7% 6 1.7% in the control/mock transfection group at
the alveolar duct level; P , .05, respectively; 27.9% 6
3.9% in the hypoxia/mock transfection group and 34.2%
6 2.8% in the hypoxia/Lac Z transfection group vs 6.6%
6 1.4% in the control/mock transfection group at the
alveolar wall level; P , .05, respectively) was ameliorated
by ANP transfection (30.7% 6 2.7% vs the hypoxia/Lac
Z transfection group at the alveolar duct level, P , .05;
23.2% 6 2.2% vs the hypoxia/Lac Z transfection group
at the alveolar wall level, P , .05). Lac Z transfection
increased the percentage of muscularization at the alveolar
duct but not the alveolar wall level in hypoxic rats
(hypoxia/Lac Z transfection group vs hypoxia/mocktransfection group at the alveolar duct level, P , .05;
Figure 3, D).
Systemic Effects of ANP Gene Transfer
Baseline plasma ANP levels in control rats were not changed
by ANP transfection. Plasma ANP levels increased with
chronic hypoxia (287.5 6 22.7 pg/mL in the hypoxia/mock
transfection group vs 136.3 6 22.3 pg/mL in the control/
mock transfection group, P , .05) were partially decreased
by ANP transfection (198.0 6 22.7 pg/mL vs the hypoxia/
mock transfection group, P , .05; Figure 4, A).
Systolic blood pressure was not changed by hypoxic
exposure or gene transfection treatment (Figure 4, B).
Polycythemia was induced by chronic hypoxia (hematocrit:
53.1% 6 2.4% in the hypoxia/mock transfection group vs
39.3% 6 1.2% in the control/mock transfection group, P ,
.05; Figure 4, C). Transfection of the ANP gene did not
change hematocrit values in control rats (Figure 4, C). Initial
body weight was similar in all 5 treatment groups. At the time
of hemodynamic measurement, hypoxic rats had lower body
weights than control rats (225.66 5.3 g in the hypoxia/mock
transfection group vs 280.6 6 7.3 g in the control/mock
transfection group, P , .05). Transfection of the ANP gene
or Lac Z did not change final body weight both in control
and hypoxic rats (Figure 4, D).CS
PFigure 4. Systemic effects of atrial
natriuretic peptide (ANP) gene transfer
in rats. Plasma ANP levels (A), mean
blood pressure (B), hematocrit value
(C), and final body weight (D) are
shown. *P < .05 versus the hypoxia/
mock transfection group; yP < .05
versus the hypoxia/b-galactosidase
transfection group; zP < .05 versus
the hypoxia/ANP transfection group.
B-Gal, b-Galactosidase transfection.
The number of each group is described
in parentheses.
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Efficient and safe vector systems are essential to successful
gene therapy against pulmonary hypertension. The present
investigation demonstrates that intratracheal gene transfer
with a novel HVJ-envelope vector resulted in marked
transgene expression in bronchial and alveolar epithelial
cells. These effects were not associated with any obvious
inflammatory cell infiltration in the lungs or any transgene
expression in other organs. The biologic relevance of this
transfection system was further supported by the ANP gene
transfer experiment, in which intratracheal gene transfer
ameliorated the development of pulmonary hypertension
and vascular remodeling in rats exposed to chronic hypoxia.
These ameliorating effects on pulmonary vascular diseases
were associated with ANP expression in the lungs, which
was not accompanied by either an increase in circulating
ANP levels or a decrease in blood pressure. These findings
suggest that ANP gene transfer with this nonviral genome
vector could be an efficient and relatively safe therapeutic
strategy against pulmonary hypertension.
By using the present vector, the reporter gene transferred
was intensely expressed in bronchial and alveolar epithelial
cells. This HVJ-envelope vector was constructed by incorpo-
rating plasmid DNA into the inactivated HVJ viral envelope,
which was deprived of the viral genome.7 The plasmid DNA
is integrated into cells by means of a specific virus-cell fusion
machinery without being degraded by endosomes or lyso-
somes. Although the present vector is one of nonviral vec-
tors, this vector thereby overcomes the issue of the limited
transfection efficiency of the previous cationic liposome for
the lung by means of these specific mechanisms.7,21,22 In
fact, a recent study demonstrated that compared with conven-
tional cationic liposomes, the HVJ-envelope vector system
confers 120-fold higher transfection efficiency in transfecting
the uterine cavity in mice.7 The biologic relevance of this
vector was demonstrated by the present experiments, in
which ANP transfection ameliorated pulmonary vascular dis-
eases in rats exposed to chronic hypoxia. These ameliorating
effects were associated with ANP expression transduced in
the lung. Furthermore, light microscopic and immunohisto-
chemical studies showed that obvious inflammatory cell infil-
tration and endothelial VCAM-1 expression was not
observed in the lungs after the transfection. These findings
are consistent with the recent reports of HVJ-envelope
vector–based gene transfer to other organs: the central ner-
vous system and the uterus.21,22 One might be concerned
about an increase in the percentage of mitral wall thickness
and the percentage of muscularization at the alveolar duct
level caused by Lac Z transfection in hypoxic rats. However,
these effects were not consistent with those on mean PA
pressure, the RV/(LV1S) ratio, and the percentage of muscu-
larization at the alveolar wall level. The levels of mean PA
pressure, the RV/(LV1S) ratio, the percentage of mitral148 The Journal of Thoracic and Cardiovascular Surgery c Julwall thickness, and the percentage of muscularization in con-
trol/mock transfected rats in our findings were comparable
with those in control rats in previous reports.18,19 Therefore
the present unfavorable but inconsistent effects of Lac Z
transfection, if any, might be related to Lac Z transfection
itself and not to the HVJ-vector system. Others might be
concerned about the incorporation of cDNA into the host
genome in this system. Although we still do not have defin-
itive data to negate this possibility in the HVJ-envelope vec-
tor system, it would not be the case because we previously
demonstrated that the transfected gene is located in the epi-
chromosome and not integrated in the chromosome by using
the HVJ-liposome system with the similar specific HVJ-cell
fusion machinery.23 Others might also be concerned about
the transgene expression in prolonged time points in this
model. Because transgene expression persists for at least 35
days in the previous HVJ-liposome system,23 which confers
transfection similarly through the specific HVJ-cell fusion
machinery, it is possible that transgene expression might
persist for more than a month in this model. Therefore the
present HVJ-envelope vector confers an efficient and
relatively safe gene transfer technology toward pulmonary
vascular disease in rats.
The present study therefore demonstrated that lung cell
transduction with ANP by using the present vector amelio-
rated pulmonary hypertension in rats. These findings are
consistent with previous reports showing that respiratory
cell transduction with various vasoactive peptides amelio-
rated pulmonary vascular diseases in rats with pulmonary
hypertension but without increased plasma levels of the
transduced peptides.24,25 Because a previous study showed
that cells transfected with the present construct, pUC/rat
ANP, release biologically active ANP peptide into the cell
culture medium,13 it is possible that ANP produced in the
transduced epithelial cells exerts paracrine effects on pulmo-
nary vascular vasoreactivity and remodeling and thereby
ameliorates pulmonary vascular diseases in rats.24 ANP plays
a pivotal role in counteracting the mechanisms involved in
the development of pulmonary hypertension. The rationale
for therapeutic supplementation of ANP against pulmonary
hypertension is 2-fold: (1) pulmonary vasodilator responses
to ANP are preserved or exaggerated in pulmonary hyperten-
sion,9,10 and (2) treatments that increase ANP levels, whether
by means of ANP infusion or neutral endopeptidase block-
ade, inhibit the development of pulmonary hypertension
and vascular diseases in rats exposed to chronic hypoxia.11,12
Therefore consistent with a previous study by Louzier and
colleagues,24 ANP gene transfer could be an effective treat-
ment strategy against pulmonary hypertension. Clinically,
compared with ANP infusion or neutral endopeptidase block-
ade, ANP lung transfection has less systemic effects and
could be clinically modulated by sildenafil administration.26
Considering the very short-term effects (10–15 minutes) of
ANP inhalation in human subjects,27 gene transfery 2008
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Papproaches with the present vector might be one of the strat-
egies with the longer duration of ANP effects. With respect to
the mechanisms, it is interesting to speculate that ANP might
inhibit smooth muscle elastase, as well as dilate pulmonary
vessels, by increasing cyclic guanosine monophosphate
levels because vascular elastase plays a pivotal role in the de-
velopment of hypoxia-induced pulmonary hypertension and
can be inhibited by cyclic guanosine monophosphate in-
crease.20,28
Taken together, HVJ-envelope vector could be a novel
nonviral vector system that could be applicable to the
treatment of pulmonary hypertension. ANP gene transfer to
the lungs by using the present vector, which has recently
become commercially available, could be a promising
therapeutic approach against pulmonary hypertension.
We thank Joji Morita, Department of Pathology II, Mie
University School of Medicine, Mie, Japan, for technical assistance
with histologic analysis.
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